Andreas Laustsen

Andreas Laustsen is an experienced professional with a background in academia and entrepreneurship. Since 2016, they have held various positions, including Professor, Associate Professor, Postdoctoral Fellow, and Co-Founder at organizations such as DTU - Technical University of Denmark, VenomAid Diagnostics, Bactolife, Chromologics, Antag Therapeutics, VenomAb IVS, Biosyntia, and the World Health Organization. In 2019, they were appointed as a Fellow at the Royal Danish Academy of Sciences and Letters (The Young Academy), and in 2020 they were appointed as a Fellow at the Young Academy of Europe. Their roles have included advising on the WHO Working Group on Snakebite Envenoming, securing grants, business development, partnerships with chemical manufacturers, market research, PR, startup competitions, pitching to investors, and strategy.

Andreas Laustsen began their educational journey in 2006 when they obtained a Certificate of Proficiency in English from the University of Cambridge. In 2007, they received a B.Sc. Eng. in Human Life Science Engineering from the DTU - Technical University of Denmark. The following year, they enrolled in the BioBusiness & Innovation Programme at Copenhagen Business School. From 2010 to 2012, they attended DTU - Technical University of Denmark and obtained an M.Sc.Eng (Honors Program) in Advanced and Applied Chemistry. During this time, they also obtained an MSc in Chimie Moléculaire from Pierre and Marie Curie University. In 2012, they attended the University of California, Davis to study Entrepreneurship in the food and healthcare industry. Finally, they completed their education in 2016 when they obtained a Doctor of Philosophy (PhD) in Molecular and Cellular Pharmacology from Københavns Universitet - University of Copenhagen.